SV001 / Shanghai Pharma - LARVOL DELTA

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. | Trial completion date: Dec 2025 ➔ Dec 2026 | Trial primary completion date: Nov 2025 ➔ Nov 2026

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=48 | Recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. | Not yet recruiting ➔ Recruiting

Enrollment open • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Immunogenicity of SV001 in Patients With Idiopathic Pulmonary Fibrosis (clinicaltrials.gov) - P2 | N=48 | Not yet recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.

New P2 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd. | Trial completion date: Mar 2025 ➔ Dec 2025 | Trial primary completion date: Nov 2024 ➔ Nov 2025

Trial completion date • Trial primary completion date • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers. (clinicaltrials.gov) - P1 | N=53 | Recruiting | Sponsor: Shanghai Synvida Biotechnology Co.,Ltd.

New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases